A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Phase 2 Recruiting 220 enrolled Taiho Oncology, Inc.

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutations.

Timeline

Start: 2023-07-31
Primary completion: 2028-08-31
Completion: 2028-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CLN-081	Small molecule	—	Oral

Indications

No indication recorded.